Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy)

Transplantation

Volumn 83, Issue 3, 2007, Pages 351-353

  Bahra, Marcus ^a   Neumann, Ulf P ^a   Jacob, Dietmar ^a   Langrehr, Jan M ^a   Berg, Thomas ^a   Neuhaus, Ruth ^a   Neuhaus, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Fibrosis progression; Hepatitis C; Liver transplantation; Sustained virologic response

Indexed keywords

ALPHA2B INTERFERON; AZATHIOPRINE; CYCLOSPORIN A; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; COURSE EVALUATION; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GRAFT INFECTION; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; SCORING SYSTEM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; RNA, VIRAL;

EID: 33847007641     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000250575.92788.aa     Document Type: Article

References (14)

1. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Eng J Med 1996; 334: 815.
2. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830.
3. Yedibela S, Schuppan D, Müller V, et al. Successful treatment of hepatitis C reinfection with interferon-α2b and ribavirin after liver transplantation. Liver Int 2005; 25: 717.
4. Bizollon T, Palazzo U, Feray C. Pilot study of the combination of alpha interferon and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500.
5. Manns M, McHutchison JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
6. Anonymous. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
7. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513.
8. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673.
9. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastrolenterology 2003; 124: 642.
10. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53.
11. Chalasani N, Manzarbeitia C, Ferenci P, et al. Pegasys Transplant Study Group. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-98.
12. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669.
13. Bizollon T, Pradat P, Mabrut JY, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909.
14. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.